+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spasticity - Epidemiology Forecast to 2030

  • ID: 4471032
  • Report
  • February 2021
  • Region: Global
  • 77 Pages
  • DelveInsight
This ‘Spasticity - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the Spasticity, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Spasticity Disease Understanding

Spasticity is defined as a condition in which certain muscles are continuously contracted. This contraction results in stiffness or tightness of the muscles and can interfere with normal movement, speech, and gait. It is also known as a motor disease which is characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyper-excitability of the stretch reflex, as one component of the upper motor neuron syndrome.

Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. The damage causes a change in the balance of signals between the nervous system and the muscles. This imbalance leads to increased activity in the muscles. Spasticity is generally found in conditions where the brain or spinal cord are damaged or fail to develop normally; these include cerebral palsy, multiple sclerosis, spinal cord injury, and acquired brain injury including stroke.

Spasticity Epidemiology

The Spasticity epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of Spasticity patients are increasing in 7MM during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Spasticity symptoms epidemiology segmented as the Prevalent Population of Spasticity, Gender-Specific Spasticity Prevalence, and Spasticity prevalence by causes. The report includes the prevalent scenario of Spasticity symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Spasticity Epidemiology

The epidemiology segment also provides the Spasticity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Spasticity associated in 7MM countries were 4,481 in 2020.
  • As per the estimates, the United States has the largest prevalent population of Spasticity.
  • Among the EU5 countries, Germany had the highest prevalent cases of Spasticity, followed by Italy. On the other hand, Spain had the lowest incident cases, with 227 cases in 2020 in EU5.
Scope of the Report
  • The Spasticity report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Spasticity Epidemiology Report and Model provide an overview of the risk factors and global trends of Spasticity in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Spasticity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Spasticity.
  • The report provides the segmentation of the Spasticity epidemiology by gender-specific spasticity prevalence in 7MM.
  • The report provides the segmentation of the Spasticity epidemiology by spasticity prevalence by different causes in 7MM.
Report Highlights
  • 11-year Forecast of Spasticity epidemiology
  • 7MM Coverage
  • Prevalent Cases according to segmentation: Gender-Specific Spasticity Prevalence
  • Prevalent Cases according to segmentation: Spasticity Prevalence by different causes
KOL Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM for the patient population of Spasticity?
  • What are the key findings of the Spasticity epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Spasticity across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burdens, and unmet needs of the Spasticity?
  • What are the currently available treatments of Spasticity?
Reasons to Buy

The Spasticity epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Spasticity market
  • Quantify patient populations in the global Spasticity market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Spasticity therapeutics in each of the markets covered
  • Understand the magnitude of Transplant Incidence.
  • Understand the magnitude of Spasticity Incidence.
  • The Spasticity epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Spasticity Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period:
2017-2030

Multiple sclerosis (MS) is a potentially severe cause of neurological disability throughout adult life. Prevalence has increased substantially in many regions since 1990. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, published in Lancet Neurology 2019 was used as the source for current prevalence rates across various geographies. This was verified by country-specific recent data wherever available. According to a 2004 study by Rizzo et al. using North American Research Committee on MS (NARCOMS) Patient Registry data, it was found that up to 84% of MS patients suffer from some degree of spasticity with approximately a third of the patients suffering from moderate to severe disease. This study also highlighted the suboptimal treatment received by the patients with up to 22% of the diagnosed patients not receiving any treatment for their spasticity.

Stroke, which is a leading cause of adult disabilities in the United States. It is a highly prevalent condition presenting roughly 2% of the total adult population. (Ovbiagele and Nguyen-Huynh, 2011) A 2016 updated report by the American Heart Association concluded that approximately 795,000 people experience a stroke in America each year, with around 610,000 of those reported to be the first incidence of stroke. Post-stroke spasticity is a major health issue for stroke survivors.
Note: Product cover images may vary from those shown

Overview

  • Spasticity in Cerebral Palsy
  • Spasticity in Multiple Sclerosis
  • Spasticity in Traumatic Brain Injury
  • Spasticity in Meningitis
  • Spasticity in Amyotrophic Lateral Sclerosis
  • Post Stroke Spasticity
  • Pathophysiology
  • Symptoms
  • Diagnosis
  • Treatment
  • Epidemiology- 7MM

Key Findings

  • Epidemiology of Spasticity in 7MM
  • Assumptions and Rationale
  • Prevalent Population of Spasticity in 7MM

United States

  • Assumptions and Rationale
  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

Germany

  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

France

  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

Italy

  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

Spain

  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

United Kingdom

  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

Japan

  • Prevalent Population of Spasticity
  • Gender-Specific Spasticity Prevalence
  • Spasticity Prevalence in MS
  • Spasticity Prevalence in Post-stroke
  • Spasticity Prevalence in Cerebral Palsy
  • Spasticity Prevalence in TBI
  • Spasticity Prevalence in SCI
  • Spasticity Prevalence by other causes

Secondary Research

Primary Research

List of Tables
Table 1: 7MM, Historical & Forecasted Spasticity Prevalence, 2017-2030
Table 2: United States, Spasticity Prevalence, 2017-2030
Table 3: United States, Gender-Specific Spasticity Prevalence, 2017-2030
Table 4: United States, Spasticity Prevalence in MS, 2017-2030
Table 5: United States, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 6: United States, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 7: United States, Spasticity Prevalence in TBI, 2017-2030
Table 8: United States, Spasticity Prevalence in SCI, 2017-2030
Table 9: United States, Spasticity Prevalence by other causes, 2017-2030
Table 10: Germany, Spasticity Prevalence, 2017-2030
Table 11: Germany, Gender-Specific Spasticity Prevalence, 2017-2030
Table 12: Germany, Spasticity Prevalence in MS, 2017-2030
Table 13: Germany, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 14: Germany, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 15: Germany, Spasticity Prevalence in TBI, 2017-2030
Table 16: Germany, Spasticity Prevalence in SCI, 2017-2030
Table 17: Germany, Spasticity Prevalence by other causes, 2017-2030
Table 18: France, Spasticity Prevalence, 2017-2030
Table 19: France, Gender-Specific Spasticity Prevalence, 2017-2030
Table 20: France, Spasticity Prevalence in MS, 2017-2030
Table 21: France, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 22: France, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 23: France, Spasticity Prevalence in TBI, 2017-2030
Table 24: France, Spasticity Prevalence in SCI, 2017-2030
Table 25: France, Spasticity Prevalence by other causes, 2017-2030
Table 26: Italy, Spasticity Prevalence, 2017-2030
Table 27: Italy, Gender-Specific Spasticity Prevalence, 2017-2030
Table 28: Italy, Spasticity Prevalence in MS, 2017-2030
Table 29: Italy, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 30: Italy, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 31: Italy, Spasticity Prevalence in TBI, 2017-2030
Table 32: Italy, Spasticity Prevalence in SCI, 2017-2030
Table 33: Italy, Spasticity Prevalence by other causes, 2017-2030
Table 34: Spain, Spasticity Prevalence, 2017-2030
Table 35: Spain, Gender-Specific Spasticity Prevalence, 2017-2030
Table 36: Spain, Spasticity Prevalence in MS, 2017-2030
Table 37: Spain, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 38: Spain, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 39: Spain, Spasticity Prevalence in TBI, 2017-2030
Table 40: Spain, Spasticity Prevalence in SCI, 2017-2030
Table 41: Spain, Spasticity Prevalence by other causes, 2017-2030
Table 42: United Kingdom, Spasticity Prevalence, 2017-2030
Table 43: United Kingdom, Gender-Specific Spasticity Prevalence, 2017-2030
Table 44: United Kingdom, Spasticity Prevalence in MS, 2017-2030
Table 45: United Kingdom, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 46: United Kingdom, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 47: United Kingdom, Spasticity Prevalence in TBI, 2017-2030
Table 48: United Kingdom, Spasticity Prevalence in SCI, 2017-2030
Table 49: United Kingdom, Spasticity Prevalence by other causes, 2017-2030
Table 50: Japan, Spasticity Prevalence, 2017-2030
Table 51: Japan, Gender-Specific Spasticity Prevalence, 2017-2030
Table 52: Japan, Spasticity Prevalence in MS, 2017-2030
Table 53: Japan, Spasticity Prevalence in Post-Stroke, 2017-2030
Table 54: Japan, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Table 55: Japan, Spasticity Prevalence in TBI, 2017-2030
Table 56: Japan, Spasticity Prevalence in SCI, 2017-2030
Table 57: Japan, Spasticity Prevalence by other causes, 2017-2030

List of Figures
Figure 1: 7MM, Historical & Forecasted Spasticity Prevalence, 2017-2030
Figure 2: United States, Spasticity Prevalence, 2017-2030
Figure 3: United States, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 4: United States, Spasticity Prevalence in MS, 2017-2030
Figure 5: United States, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 6: United States, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 7: United States, Spasticity Prevalence in TBI, 2017-2030
Figure 8: United States, Spasticity Prevalence in SCI, 2017-2030
Figure 9: United States, Spasticity Prevalence by other causes, 2017-2030
Figure 10: Germany, Spasticity Prevalence, 2017-2030
Figure 11: Germany, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 12: Germany, Spasticity Prevalence in MS, 2017-2030
Figure 13: Germany, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 14: Germany, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 15: Germany, Spasticity Prevalence in TBI, 2017-2030
Figure 16: Germany, Spasticity Prevalence in SCI, 2017-2030
Figure 17: Germany, Spasticity Prevalence by other causes, 2017-2030
Figure 18: France, Spasticity Prevalence, 2017-2030
Figure 19: France, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 20: France, Spasticity Prevalence in MS, 2017-2030
Figure 21: France, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 22: France, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 23: France, Spasticity Prevalence in TBI, 2017-2030
Figure 24: France, Spasticity Prevalence in SCI, 2017-2030
Figure 25: France, Spasticity Prevalence by other causes, 2017-2030
Figure 26: Italy, Spasticity Prevalence, 2017-2030
Figure 27: Italy, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 28: Italy, Spasticity Prevalence in MS, 2017-2030
Figure 29: Italy, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 30: Italy, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 31: Italy, Spasticity Prevalence in TBI, 2017-2030
Figure 32: Italy, Spasticity Prevalence in SCI, 2017-2030
Figure 33: Italy, Spasticity Prevalence by other causes, 2017-2030
Figure 34: Spain, Spasticity Prevalence, 2017-2030
Figure 35: Spain, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 36: Spain, Spasticity Prevalence in MS, 2017-2030
Figure 37: Spain, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 38: Spain, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 39: Spain, Spasticity Prevalence in TBI, 2017-2030
Figure 40: Spain, Spasticity Prevalence in SCI, 2017-2030
Figure 41: Spain, Spasticity Prevalence by other causes, 2017-2030
Figure 42: United Kingdom, Spasticity Prevalence, 2017-2030
Figure 43: United Kingdom, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 44: United Kingdom, Spasticity Prevalence in MS, 2017-2030
Figure 45: United Kingdom, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 46: United Kingdom, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 47: United Kingdom, Spasticity Prevalence in TBI, 2017-2030
Figure 48: United Kingdom, Spasticity Prevalence in SCI, 2017-2030
Figure 49: United Kingdom, Spasticity Prevalence by other causes, 2017-2030
Figure 50: Japan, Spasticity Prevalence, 2017-2030
Figure 51: Japan, Gender-Specific Spasticity Prevalence, 2017-2030
Figure 52: Japan, Spasticity Prevalence in MS, 2017-2030
Figure 53: Japan, Spasticity Prevalence in Post-Stroke, 2017-2030
Figure 54: Japan, Spasticity Prevalence in Cerebral Palsy, 2017-2030
Figure 55: Japan, Spasticity Prevalence in TBI, 2017-2030
Figure 56: Japan, Spasticity Prevalence in SCI, 2017-2030
Figure 57: Japan, Spasticity Prevalence by other causes, 2017-2030

Note: Product cover images may vary from those shown
Adroll
adroll